FDA device chief under fire: Did Dr. Jeffrey Shuren lie to Congress?
March 10, 2011 by MassDevice staff
An apparent untruth given during during testimony to a U.S. House committee by Dr. Jeffrey Shuren — chief of the FDA's medical device arm — is creating a kerfluffle among scientists and bloggers.
Shuren
MASSDEVICE ON CALL: An evident untruth made during questioning by a U.S. House committee is landing Dr. Jeffrey Shuren, head of the FDA' medical device branch, in hot water with scientists and bloggers.
Testifying before a House Energy & Commerce Committee on direct-to-consumer genetic tests last summer, Shuren told Rep. Henry Waxman (D-Calif.) that companies that make the tests do not conduct their own research.
- Show full page
- Login to post comments
-
Permalink
RECENT BLOG POSTS
- A cure for coffee breath?
- A Goldilocks approach to leaky blood vessels: Not too stiff, but not too loose
- Optimizing electronic medication administration records
- A bold new vision for Meditech
- Medtech storytelling in the era of comparative effectiveness
- Medical device sales: Wright Medical's pilot program on rep-less sales process worth watching
- Raising an early warning in the ICU: T3
- Staff shakeup underway at Russian medical device regulator
- Heart Rhythm Society 2013 Scientific Session wrap-up
- Physician blogger insights on social media
Navigation
NEWS
Devon Medical gains extriCARE CE Mark
Devon Medical wins CE Mark approval in the European Union for its portable extriCARE negative...
Prosthetics makers sue Medicare over payment rules
The American Orthotic and Prosthetic Assn. sues Medicare and the U.S. Health & Human Services...
Pluristem launches Phase I clinical trial to treat tendonitis with stem cells
Pluristem is seeking clinical proof that stem cell therapy can benefit patients with chronic...
GE Healthcare unveils soft tissue imaging technology
GE Healthcare introduces Mavric SL, a novel magnetic resonance imaging technique for joint...
Hip implants: Johnson & Johnson's DePuy will stop selling metal-on-metal implants
Johnson & Johnson subsidiary DePuy Orthopaedics plans to phase out sales of all of its metal-on-...
